Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

[1]  E. Jabbour,et al.  Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. , 2022, JAMA oncology.

[2]  R. Foà,et al.  P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL , 2022, HemaSphere.

[3]  M. Konopleva,et al.  High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse , 2022, Blood advances.

[4]  S. Kasner,et al.  Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee , 2022, Journal of Hematology & Oncology.

[5]  R. Foà,et al.  INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia , 2021, Blood advances.

[6]  G. Rosti,et al.  Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. , 2021, Blood.

[7]  R. Foà,et al.  Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. , 2021, Blood.

[8]  E. Jabbour,et al.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms , 2021, Leukemia.

[9]  R. Foà,et al.  Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. , 2020, The New England journal of medicine.

[10]  B. Druker,et al.  Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. , 2020, Blood.

[11]  M. Konopleva,et al.  Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors , 2019, American journal of hematology.

[12]  M. Konopleva,et al.  Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia , 2019, Blood.

[13]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. , 2018, The Lancet. Haematology.

[14]  M. Trková,et al.  Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. , 2017, Blood.

[15]  P. Chevallier,et al.  Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Radich,et al.  US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.

[17]  M. Konopleva,et al.  Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis , 2016, Cancer.

[18]  J. Cayuela,et al.  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. , 2016, Blood.

[19]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[20]  Z. Estrov,et al.  Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.

[21]  M. Konopleva,et al.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2015, Haematologica.

[22]  T. Clackson,et al.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.

[23]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.